LANCET: Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial

Background: Drug-eluting stents with durable biocompatible or biodegradable polymers have been developed to address the risk of thrombosis associated with first-generation drug-eluting stents. We aimed to compare the safety and efficacy of a biodegradable polymer-coated biolimus-eluting stent with a thin-strut everolimus-eluting stent coated with a durable biocompatible polymer.

LANCET: Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial

Background: Third-generation biodegradable polymer drug-eluting stents might reduce the risk of stent thrombosis compared with first-generation permanent polymer drug-eluting stents. We aimed to further investigate the effects of a biodegradable polymer biolimus-eluting stent compared with a durable polymer-coated sirolimus-eluting stent in a population-based setting.

JACC. LEADERS: 5-Year Follow-Up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Biodegradable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer- Final report of the LEADERS study

JACC. Biodegradable polymer-based Biolimus A9-eluting stent for the treatment of infrapopliteal arteries in critical limb ischemia: long-term clinical and angiographic follow-up

JACC. 5-year Clinical Outcomes of Biodegradable Polymer Biolimus-eluting Stents versus Durable Polymer Sirolimus-eluting Stents in Patients with and without Diabetes Mellitus: a LEADERS Sub-study

Background: Patients with diabetes mellitus (DM) undergoing percutaneous cardiovascular intervention (PCI) represent a challenging population with higher risk of adverse events compared to non-diabetic patients. We investigated the impact of DM on long-term clinical outcomes of biolimus-eluting stents (BES) with biodegradable polymer versus sirolimus-eluting stents (SES) with durable polymer within the randomized multi-center all-comers LEADERS trial through 5 years.

JACC. Drug-Eluting Stents for the Treatment of Left Main Coronary Artery Disease with Bifurcated Lesions: A Comparison with Sirolimus, Paclitaxel, Zotarolimus (Endeavor Resolute), BiolimusA9, EPC Capture and Everolimus-Eluting Stent

Background: The aim of this study is to compare the safety, efficacy and durability of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of patients with left main coronary arteries (LMT) stenosis

JACC. Biodegradable-Polymer Biolimus Eluting Stents Show Better Antiproliferative Efficacy And Vascular Healing Pattern Than Permanent-Polymer Paclitaxel Eluting Stents in a Preclinical Coronary Model

Background: Second-generation drug eluting stents (DES) have shown a high efficacy in terms of restenosis prevention, like first-generation DES, with reduced rates of stent thrombosis, especially late stent thrombosis. The suggested mechanism for this superiority is a better morphological and functional healing response. The objective of this study is to compare the efficacy and safety results of 2 different, first and second-generation, DES in a swine model of normal coronary arteries

JACC. Long-Term Outcomes of Biodegradable Polymer Drug-Eluting Stents versus Durable Polymer Sirolimus-Eluting Stents in Patients with Diabetes: A Pooled Analysis of Individual Patient Data from the ISAR-TEST 4 and LEADERS Randomized Trials

Background: Patients with diabetes show higher rates of restenosis and stent thrombosis following PCI. Optimal for treatment of patients with diabetes is not known and no stent has demonstrated superior efficacy or safety. Late stent thrombosis is associated with impaired endothelial coverage and adverse vessel remodeling- both features of delayed arterial healing caused by permanent polymer drug-eluting stents (DES). Biodegradable polymer DES offer improved biocompatibility and may improved long-term outcomes.

JACC. Drug-Eluting Stents for the Treatment of Very Long Coronary Artery Stenosis with Diabetes Mellitus: A Comparison with Sirolimus, Paclitaxel, Zotarolimus (Endeavor Resolute), BiolimusA9, EPC Capture and Everolimus-Eluting Stent

Background: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of stenting in patients with diabetic very long coronary lesion (VLL) (lesion length ≥40 mm).

JACC. Drug-Eluting Stents for the Treatment of Small Coronary Artery with Diabetes Mellitus: A Comparison with Sirolimus, Paclitaxel, Zotarolimus (Endeavor Resolute), BiolimusA9, EPC Capture and Everolimus-Eluting Stent

Background: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of treatment of small coronary artery disease with diabetes mellitus (DM).

JACC. Clinical Outcome Of Biolimus-Eluting Versus Sirolimus-Eluting Coronary Stent Implantation In Patients With And Without Diabetes Mellitus: A SORT OUT V Substudy

Background: Diabetes is associated with an increased risk of major adverse cardiac events (MACE) following percutaneous coronary intervention.

JACC. Neointimal growth patterns after between biodegradable polymer biolimus-eluting or permanent polymer everolimus-eluting stent implantation assessed with newly developed “spread-out neointimal topography”: Results from ISAR-TEST6 OCT trial

Background: Neointimal growth patterns of new generation drug-eluting stents are not yet fully elucidated. We developed a new visualization method and compared neointimal growth patterns between biodegradable polymer biolimus-eluting stent (BES) and permanent polymer everolimus-eluting stent (EES) using optical coherence tomography (OCT).

JACC. Efficacy and Safety of Biodegradable Polymer Biolimus-Eluting Stents versus Durable Polymer Everolimus-Eluting Stents in Diabetic Patients - A Prospective Non-Randomized Single Center Long Term Comparison

Background: Biodegradable polymer drug eluting stents improve safety and efficacy when compared to durable polymer drug eluting stents, but this may not be true in diabetic patients.

JACC. Three Year Follow up of a Randomized Comparison of Nobori, Biolimus A9 Eluting Stent(BES) with Cypher, Sirolimus Eluting Stent(SES) for Coronary Revascularization in Japanese Population

Background: Nobori stent (Terumo Co., Tokyo Japan), is the new concept Drug Eluting Stent which has unique bioabsorbable polymer (Poly-Lactic Acid) and the anti-proliferative agent Biolimus A9. We investigated the safety and the efficacy of Nobori stent comparing to Cypher stent in Japanese population by a single blinded 3:2 randomized trial and met the primary endpoint, non inferiority in TVF. This is the first report of three year clinical follow up data of Nobori Biolimus Eluting stent compared to Cypher Sirolimus Eluting stent in Japanese population.

JACC. Drug-eluting stent with biodegradable polymer in patients with STEMI – short and long term outcomes: data from e-NOBORI and NOBORI 2 trials

Background: With the introduction of drug eluting stents (DES) in this decade, treatment of patients with STEMI with these devices has emerged as a rational PCI alternative. In spite of the unquestionable benefits of DES in terms of reduction of restenosis and TVR, specific concerns have arisen with regard to their short- and long-term safety. We aim to assess short- and long-term outcomes in STEMI patients treated with Nobori, DES with biodegradable polymer.